Printer Friendly

A Systematic Review and Meta-Analysis on a Disease in TCM: Astragalus Injection for Gathering Qi Depression.

1. Introduction

Qi is a subtle substance in human body in traditional Chinese medicine (TCM) theory. As one of the leading substances, the function of Qi covers almost all aspects of human function. Qi deficiency causes pale face, shortness of breath, weakness of limbs, dizziness, diarrhea, and other symptoms. Qi deficiency is associated with a variety of diseases, especially cardiovascular and cerebrovascular diseases [1, 2]. According to the guidance of TCM, the use of Atractylodes macrocephala, Astragalus, and even medical qigong has played a therapeutic effect on many diseases caused by Qi deficiency [3-5]. Gathering Qi, one of the Qi in human body, known as Zong Qi or "Da Qi" frequently, is first mentioned in "Huang Di Nei Jing:" "Five cereals which enters the stomach were divided into three portions: dross, essence, and gathering Qi. Gathering Qi is accumulated in the chest, out of the throat," and its function is "active heart to push blood as well as lung to breath." There are many supplements in the generations, Yu Jiayan, one of famous doctors lived in the Qing dynasty, believe that gathering Qi can dominate a patient whether to survive [6]. And, Zhang Xichun proposed that gathering Qi has a close relationship with general health, and it is a series of complicated symptoms when gathering Qi dysfunction, such as shortness of breath, asthma, chest tightness, fatigue, and palpitation, is the most widely described description. While the gathering Qi depression, or Zong Qi depression, usually has the same clinical symptoms but more severe, dyspnea is a common symptom in acute and critical illness. Zhang Xichun also proposed a treatment while perfecting the theory: Shengxian decoction, the most famous gecoction of traditional Chinese medicine for the treatment of Zong Qi depression. The composition of Shengxian decoction is as follows: Astragalus membranaceus (huangqi), Anemarrhena (zhimu), Radix Bupleuri (chaihu), Rhizoma cohosh (shengma), and Platycodon grandiflorum (jiegeng). This decoction is widely used to treat the symptoms of Zong Qi deficiency characterized by fatigue and shortness of breath [7, 8]. Astragalus membranaceus plays a dominate role and described by Zhang Xichun as "best at filling the Da Qi in the chest." Pharmacological studies have shown that Astragalus and its extracts showed immunostimulant, antioxidative, and cardioprotective effects [9, 10]. All these are attributed to the function of Astragalus in increasing Zong Qi. However, in the study of Astragalus, there is a little emphasis on Zong Qi depression rather than specific diseases in modern medicine. This condition hinders our assessment of the role of Astragalus. Thus, we regarded sinking of gathering Qi as an independent disease and corresponded to western medicine, founded it is similar to many disease and closest to heart failure (HF), respiratory failure (RF), acute respiratory distress syndrome (ARDS), and acute lung injury (ALI). The above 4 diseases cannot completely represent the suffocation, but they have typical clinical symptoms (Figure 1). Astragalus injection is made of a sterilized extraction solution from Astragalus and widely used in clinical practice [11]. Similar to Astragalus decoction, the main components of Astragalus injection are astragalosides, polysaccharides, flavones, and amino acids [12]. In a meta-analysis study, both Astragalus injection and Astragalus granule have achieved certain curative effects [13]. However, because the drug in the form of injection can play a directly role without oral absorption, there is a better curative effect of uningested chemicals in the blood [14]. So far, no research has been done to unify the above diseases into Zong Qi depression; hence, we searched for clinical trials of Astragalus injection for the treatment of them and conducted systematic and meta-analysis to exploring the therapeutic effect of Astragalus injection on diseases with Zong Qi depression.

2. Methods

A systematic review and meta-analysis of clinical studies assessed the efficacy of Astragalus injection combined with routine therapy for Zong Qi depression which includes heart failure, respiratory failure, acute respiratory distress syndrome, and acute lung injury. We divided the mortality into short-term (less than 1 month) [15] and long-term (1 month to 1 year) [16], and the distance of 6-minute walking test after continuous use of Astragalus injection for 7 days, 14 days, and 28 days for evaluation of therapeutic effect in order to evaluate the therapeutic effect of Astragalus injection.

2.1. Search Strategy. We conducted a literature search on Pubmed, China National Knowledge Infrastructure (CNKI), WanFang Data, and Vip citation databases from inception to March 19, 2019. Search strategy and details are follows: (Cardiac Failure or Heart failure or Shock Lung or Acute Respiratory Distress Syndrome or ARDS or ALI or Acute Lung Injury or Respiratory Insufficiency or Respiratory Failure) and (Astragalus injection or Huangqi injection). Research was carried out on filtering out nonclinical trials during search.

2.2. Study Selection. This study of meta-analysis was to assessing the therapeutic effect of Astragalus injection for Zong Qi depression. The primary outcomes were mortality which is divided into 1-month mortality and 1-year mortality. The secondary outcome indicator is distance of 6-minute walk test (6MWT). The following inclusion criteria were required for a study to be eligible for the meta-analysis: (1) a clinical study, at least one disease of heart failure, respiratory failure, acute respiratory distress syndrome, or acute lung injury, as long as the diagnosis of the above four diseases, regardless of which version of the clinical practice guide; (2) a study conducted in a population aged 18 years or older; (3) a study including the use of Astragalus injection without other Chinese medicine or Chinese medicine extracts; and (4) a study including report mortality or 6-minute walk test. We excluded reviews or studies on animals.

2.3. Data Extraction. Retrieved studies were selected and appraised by two trained reviewers (YH and YY). Disagreement were discussed and decided with a third reviewer (PH). After that, two independent reviewers (YH and YY) extracted data from the included studies. For each eligible study, we extracted data on the name of researcher and year of publication, diseases reported in the study, sample size including the number of subjects in the experimental group and control group, participant characteristics (age and sex), course of disease, routine therapy, application methods of Astragalus injection, Outcome indicators, and side effects.

2.4. Statistical Methods. We conducted this meta-analysis to calculate the therapeutic effect of Astragalus injection on the mortality of patients with Zong Qi depression using a fixed-effects model. The random effect model was used to calculate the therapeutic effect of Astragalus injection on the 6-minute walk test. The effect of selection of binary variables is RR value, while that of continuous variables is mean difference. Point estimates and 95% confidence intervals (CI) of each effect were calculated. Heterogeneity test statistical method uses Q test, gets probability by [chi square] analysis, and quantitatively describes the degree of heterogeneity by [I.sup.2] value to evaluate the size of heterogeneity. Sensitivity analysis is done by omitting one report at a time from the analysis and assessing its impact on overall results. Furthermore, the potential publication bias was analyzed by funnel plots. The data extracted from the literature were analyzed by Revman 5.3, and a 2-sided P value less than 0.05 was considered statistically significant.

The quality of clinical studies was assessed according to the Cochrane Collaboration's Tool for Assessing Risk of Bias (ROB table). This scale awards nine scores to each study as follows: random sequence generation, distribution methods, participant blindness, blindness of outcome evaluation, incomplete outcome data, selective reporting, and other biases, including the description of these seven items, including "high risk," "low risk," and "unclear risk" in the three judgements, and the risk assessment results are represented by a bias risk map. Based on the results of this systematic review, use the GRADE system to recommend a grading recommendation method to evaluate the quality of evidence. Divide the quality of the indicators included in this study into high: further research will not change the credibility of the results; medium: further research may alter the reliability and outcome of the treatment; low: further studies are likely to alter the reliability and outcome of the treatment; and very low: any evaluation of efficacy and results are uncertain. The assessment results are presented in the summary of findings table (SoF table).

3. Results

3.1. Study Selection. From the searches for systematic reviews, 1343 records were identified including PubMED (n = 6), CNKI (n = 307), WanFang Data (n = 575), and Vip citation databases (n = 455). After excluding 609 duplicate studies, 627 were excluded based on title/abstract contents. The full texts of 111 records were read, and 21 studies involving 1868 participants were ultimately included (Figure 2).

3.2. Study Characteristics. A total of 21 eligible studies involving 1868 participants were included in this study, including one reported on ARDS [17], one on respiratory failure [18], 18 on heart failure [19-36], and one on both of respiratory failure and heart failure [37]. Of the 18 reported heart failure studies, four reported pulmonary heart disease as a comorbidity [22, 26, 28, 29], and the others are chronic or congestive heart failure (Table 1 provided in Supplementary Materials). All 21 studies were conducted China.

Studies on HF included used a variety of diagnostic criteria, mainly including ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult [38], Framingham criteria [39], and Guidelines for the diagnosis and management of chronic heart failure which was made by Chinese Society of Cardiology of Chinese Medical Association [40]. According to these clinical practice guidelines, cardiotonic, diuretic, vasodilator, and oxygen inhalation are used to control the primary disease and eliminate the inducement of heart failure. The other three diseases are also diagnosed and treated according to the corresponding clinical practice guidelines [41].

3.3. Outcomes

3.3.1. Primary and Secondary Outcomes. In reporting mortality rate as an outcome indicator 13 studies, 8 studies [18,21, 26, 28, 29, 33, 36, 37] including 684 patients reported a one-month mortality rate, and 6 studies [17, 19,20,25, 30, 36] including 388 patients reported a one-year mortality rate. The use of Astragalus injection can reduce the one-month mortality (OR, 0.26 [0.12, 0.61], 95% CI, P = 0.002) and one-year mortality (OR, 0.38 [0.20, 0.69], 95% CI, P = 0.002) of patients with Zong Qi depression (Figure 3). Both of two indicators have a low heterogeneity (p = 0.90, [I.sup.2] = 0% and P = 0.78, [I.sup.2] = 0%).

Two studies [22, 34] including 160 patients reported 6-minute walking distance after 7 days with Astragalus injection, seven studies [19, 23, 24, 27, 31-33] including 735 patients reported 14 days, and two studies [21, 35] including 216 patients for 28 days. Pooled estimates showed that the distance of 6-minute walking test increased (MD, 91.60 [6.89,176.31], 95% CI, P = 0.03) after 7 days with Astragalus injection, as well as 14 days (MD, 22.62 [13.80, 31.43], 95% CI, P < 0.00001) and 28 days (MD, 108.31 [30.02, 186.59], 95% CI, P = 0.007), Figure 4. Among these indicators, the heterogeneity between studies is greater, which is P < 0.00001, [I.sup.2] = 96%, P = 0.03, [I.sup.2] = 57% and P < 0.007, [I.sup.2] = 98%. The reasons for this high heterogeneity will be discussed in Section 4.

3.3.2. Side Effect. One patient developed dizziness, two patients developed feeling of fullness in the head, one patient had elevated serum urea nitrogen, three patients had first dose hypotension, one patient had hypotension, one patient had sinus bradycardia, and one patient had second degree atrioventricular block in all included studies. Among them, some patients can alleviate by themselves, and some have been alleviated by reducing dosage or symptomatic treatment.

3.3.3. Sensitivity Analyses. In sensitivity analysis, we found that excluding any study would not significantly change the results.

3.3.4. Bias Risk Assessment. The assessment of ROB is summarized. The quality of most studies is relatively low. Most studies have mentioned the use of random allocation, but only a small number describe the way of random allocation, and almost no research reports allocation concealment. Concealment of subjects is feasible when injected with Astragalus injection, but no studies have reported it. All studies were unable to blind the interventions to participants (Figures 5 and 6).

There were five main outcomes in this study. The mortality was followed up for one month and one year, and the walking distance of 6-minute walk test after 7 days, 14 days, and 28 days with Astragalus injection. The quality of evidence for each outcome is very low (Figure 7). The main reasons are unreported double-blind methods and large inconsistencies.

3.3.5. Publication Bias. The funnel plots for publication bias show no obvious asymmetry, and it indicated that the pooled results were not influenced by the publication bias (Figure 8).

4. Discussion

In this meta-analysis, we searched clinical studies of Astragalus injection in the treatments of four diseases that accord with clinical feature of Zong Qi depression: heart failure, respiratory failure, acute respiratory distress syndrome, and acute lung injury and found that Astragalus injection combined with routine medicine treatments on gathering Qi depression can reduce the short-term mortality as well as long-term mortality. Furthermore, 7 days, 14 days, and 28 days continuous use of Astragalus injection can increase the 6-minute walking test of Zong Qi depression patients. These findings are supported by precious systematic review on heart failure [42]; however, the therapeutic of Astragalus injection on the other diseases are rarely studied. This shows that application scope of Astragalus injection still needs to be explored; therefore, we cautiously suggest that it can be considered combining Astragalus injection with routine treatment to reduce mortality and improve clinical efficacy when facing gathering Qi depression.

In traditional Chinese medicine theory, the lungs govern respiration which means they inhale "pure Qi" from air and exhale "dirty Qi," the combination of air from the lungs and food Qi from the spleen forms gathering Qi which derives Yang Qi of the heart and the lung. Thus function of gathering Qi is closely related to the whole body condition and more closely to circulation and respiratory function, as Zhang Xichun said "gathering Qi actually controls general health while remains in cheat." Like Qi deficiency, when there is insufficient of Zong Qi, we often show symptoms such as fatigue and shortness of breath, which leads to decreased activity tolerance [2, 43]. With the development of modern medicine, we found that the function of Zong Qi is related to the respiratory system, circulatory system, nervous system, and even reproductive system. And, the number of diseases that treated by the theory of Zong Qi is increasing, including but not limited to chronic congestive heart failure, coronary heart disease, senile cardiac arrhythmias, sinus bradycardia, vertebral basilar artery insufficiency, the complete atrioventricular block, frequent room premature beat, viral myocarditis, quickness, sick sinus syndrome, rheumatic heart disease, atrial fibrillation, cor pulmonale, bronchial asthma and other respiratory system diseases, circulatory system disease, and dizziness, neurosis, tension headaches, gastroptosis, abdominal distention, diarrhea, urinary incontinence, retention of urine, premature ejaculation, functional uterine bleeding, and other system diseases [44]. While gathering depression is a more serious stage, according to Zhang Xichun "people feel that exhalation and inhalation cannot be continuous, that means Da Qi is about to become weak," we choose asthma as the main symptom of gathering Qi dysfunction and selected four diseases with most typical symptoms for systematic review and metaanalysis: heart failure, respiratory failure, acute respiratory distress syndrome, and acute lung injury. After the search, we only found and included 3 of them. In the literature included in this study, the symptoms of the patients included lethargy, cyanosis of lips, chest pain, cough and expectoration, dyspnea, palpitation, and edema. These clinical manifestations are consistent with the disease Zong Qi depression described by Zhang Xichun. It is precisely in his theory that Astragalus is the first choice for the treatment of Zong Qi depression. In previous studies, traditional Chinese medicine has achieved good results in the treatment of heart and lung diseases. When thinking that patients need to nourish Yang Qi, doctors often use drugs such as ginseng and aconite [45]. In recent years, Astragalus membranaceus has increasingly appeared in drugs used to treat heart and lung diseases, such as Qishen Yiqi dripping pills and Qili Qiangxin capsules [46, 47]. Therefore, we think it is necessary to evaluate the efficacy of Astragalus injection in the treatment of these diseases.

Obviously, this does not completely cover all the diseases contained in Zong Qi depression, and at the same time, some of the symptoms are not completely subordinate to it [48]. On the one hand, it is attributed to the fact that function of Zong Qi is too broad to be summarized clearly; on the other hand, it is also due to the lack of objective evaluation criteria for the concept of Qi deficiency. Zong Qi depression has been widely studied and discussed as a symptom, but this is far from the original intention of ancient Chinese medicine doctors.

In the selection of outcome indicators, our first consideration is the mortality rate. Meanwhile, 6-minute walking test is a gold indicator for assessing cardiopulmonary functions by test activity tolerance. Qi is considered to be the most essential substance in human beings, directly reflecting life activities and activity tolerance, and Astragalus is one of the first choices for Qi in TCM theory, especially good at relieving fatigue and improving activity tolerance [49]. In this study, Astragalus injection can reduce the mortality and increase the distance of 6-minutes walking test of patients with Zong Qi depression, which is in line with the theory of traditional Chinese medicine. In other clinical trials on respiratory and circulatory systems, Astragalus injection has also yielded good results [50-52].

There is no such dosage form of injection in traditional Chinese medicine theory. In the practice of Chinese doctors for thousands of years, drugs act on the human body in the form of water decoction. With the support of healthy atmosphere, the spleen and stomach work together to help the drug effectively become absorbed and play a therapeutic role. However, the decoction of traditional Chinese medicine has some weaknesses on solubility and stability [53]. Therefore, it is very important to develop new dosage forms for the application of Chinese herbal medicine [54]. At the same time, due to the standardization of the manufacture of traditional Chinese medicine, the difficulty of homogenization of quality and the complexity of components, the adverse reactions occurred frequently in the process of application. Therefore, it is necessary to strengthen the systematic research work of traditional Chinese medicine injection and the supervision and control of clinical rational drug use, and conduct high-quality clinical trials to clarify the use of traditional Chinese medicine injection [55].

For a long time, we have been using traditional Chinese medicine theory, in other words, treatment based on syndrome differentiation, to guide the use of traditional Chinese herbs to treat diseases in Western medicine. We seem to have been used to saying that treatment of chronic heart failure with Astragalus injection is under the theoretical guidance of Yi Qi Sheng Yang theory (a commonly used theory in Chinese medicine was proposed by Zhang Xichun). This will definitely affect our understanding and evaluation of the efficacy of traditional Chinese medicine to a certain extent. Therefore, we innovatively produced a systematic review which contains diseases in TCM theory. To our knowledge, this is the first meta-analysis to comprehensively summarize results regarding heart failure, respiratory failure, and acute respiratory distress syndrome as an independent disease; at the same time, it is also the first systematic review of treating diseases in TCM theory. We recommend take more similar studies to verify Chinese medicine theory and efficacy to change the current situation of diagnosis with western medicine and treatment with traditional Chinese medicine.

This study included 21 studies with 4 diseases, so a high heterogeneity is neither surprising nor avoidable. On the one hand, the dose of traditional Chinese medicine used varies greatly; on the other hand, the included patients suffer from different basic diseases. Such problems also exist in the other systematic reviews of TCM fields. This indicates that we need relevant studies on the usage and dosage of Chinese medicine to explore the best curative effect to guide clinical treatment and establish the corresponding regulations. We believe that it is necessary to establish and improve the system of disease names with Chinese medicine characteristics. Using TCM theory to guide the treatment of diseases in TCM theory may get better curative effect. There may be a long way to go, but we should start now. In addition, the quality of included studies was low, suggesting the need for high-quality clinical studies.

https://doi.org/10.1155/2020/2803478

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors express their gratitude for financial support from the National Natural Science Foundation of China (grant nos. 81673934, 81973608, and 81774146), Beijing Municipal Natural Science Foundation (grant no. 7192083), Major Projects during the 13th Five-Year Plan (grant no. 2017ZX10305501), and "13th Five-Year" National Science and Technology Major Project for New Drugs (No: 2019ZX09734001).

Supplementary Materials

Table 1: basic information on the studies included. (Supplementary Materials)

References

[1] W. Zhou and Y. Wang, "A network-based analysis of the types of coronary artery disease from traditional Chinese medicine perspective: potential for therapeutics and drug discovery," Journal of Ethnopharmacology, vol. 151, no. 1, pp. 66-77, 2014.

[2] M. M. Ko, J. A. Lee, M. H. Cha, B. K. Kang, and M. S. Lee, "Stroke in traditional Korean medicine: a nine-year multi-centre community-based study in South Korea," Scientific Reports, vol. 6, no. 1, p. 28286, 2016.

[3] K. W. Chen and F. D. Turner, "A case study of simultaneous recovery from multiple physical symptoms with medical Qigong therapy," The Journal of Alternative and Complementary Medicine, vol. 10, no. 1, pp. 159-162, 2004.

[4] L. Zhang, J. L. Shergis, L. Yang et al., "Astragalus membranaceus (Huang Qi) as adjunctive therapy for diabetic kidney disease: an updated systematic review and meta-analysis," Journal of Ethnopharmacology, vol. 239, p. 111921, 2019.

[5] J. Wang, W. Feng, S. Zhang et al., "Ameliorative effect of Atractylodes Macrocephala essential oil combined with Panax ginseng total saponins on 5-fluorouracil induced diarrhea is associated with gut microbial modulation," Journal of Ethnopharmacology, vol. 238, Article ID 111887, 2019.

[6] R. X. Feng, Z. Z. Zhang, and Z. K. Zhang, "Exploration and analysis of Zhang Xichun's theory formation of Da Qi in the chest and the collapse," Journal of Traditional Chinese Medicine, vol. 57, p. 1455, 2016.

[7] Y. Q. Chen, W. Cheng, D. F. Lin, and Z. Y. Zhang, "Clinical observation on Shengxian decoction in treating chronic heart failure with cardiopulmonary Qi deficiency syndrome," Chinese Medicine Modern Distance Education of China, vol. 17, p. 69, 2019.

[8] H. N. Jie, "Treatment of 23 cases of chronic fatigue syndrome with Jiawei Shengxian decoction," Jiangsu Journal of Traditional Chinese Medicine, pp. 1001-9537, 1998.

[9] X. Li, L. Qu, Y. Dong et al., "A review of recent research progress on the astragalus genus," Molecules, vol. 19, no. 11, pp. 18850-18880, 2014.

[10] P. Liu, H. Zhao, and Y. Luo, "Anti-aging implications of astragalus membranaceus (Huangqi): a well-known Chinese tonic," Aging and Disease, vol. 8, no. 6, p. 868, 2017.

[11] Y.-L. Piao and X.-C. Liang, "Astragalus membranaceus injection combined with conventional treatment for viral myocarditis: a systematic review of randomized controlled trials," Chinese Journal of Integrative Medicine, vol. 20, no. 10, pp. 787-791, 2014.

[12] S. Fu, J. Zhang, F. Menniti-Ippolito et al., "Huangqi injection (a traditional Chinese patent medicine) for chronic heart failure: a systematic review," PLoS One, vol. 6, no. 5, Article ID e19604, 2011.

[13] Z. L. Liu, Z. J. Liu, J. P. Liu, M. Yang, and J. Kwong, "Herbal medicines for viral myocarditis," Cochrane Database of Systematic Reviews, Article ID CD003711, p. D3711, 2016.

[14] H. Li, H. Wan, T. Xia et al., "Therapeutic angiogenesis in ischemic muscles after local injection of fragmented fibers with loaded traditional Chinese medicine," Nanoscale, vol. 7, no. 30, pp. 13075-13087, 2015.

[15] K. W. Prins, J. M. Neill, J. O. Tyler, P. M. Eckman, and S. Duval, "Effects of beta-blocker withdrawal in acute decompensated heart failure: a systematic review and metaanalysis," JACC: Heart Failure, vol. 3, no. 8, pp. 647-653, 2015.

[16] K. P. Wagenaar, B. D. L. Broekhuizen, T. Jaarsma et al., "Effectiveness of the European society of cardiology/heart failure association website 'heartfailurematters.org' and an e-health adjusted care pathway in patients with stable heart failure: results of the 'e-Vita HF' randomized controlled trial," European Journal of Heart Failure, vol. 21, no. 2, pp. 238-246, 2019.

[17] Y. H. Wang, L. Zheng, and B. N. Ye, "Clinical study on the effect of astragalus injection on pulmonary vascular permeability in patients with acute respiratory distress syndrome," Pharmacology and Clinics of Chinese Materia Medica, vol. 31, p. 169, 2015.

[18] X. Y. Fan, "Clinical observation on 92 cases of severe cor pulmonale complicated with respiratory failure treated with astragalus injection," Chinese Journal of Misdiagnostics, vol. 3, p. 1519, 2003.

[19] J. M. Chang and X. Wang, "Clinical observation of 25 cases of chronic heart failure treated with carvedilol and Astragalus injection," Shanxi Medical Journal, p. 601, 2006.

[20] B. Y. Guo, "Clinical observation on 65 cases of congestive heart failure treated with astragalus injection," Journal of Xinjiang Medical University, p. 662, 2005.

[21] B. Q. Jia and L. Xu, "Observation on therapeutic effect of astragalus injection on chronic heart failure," Chinese Journal of Clinical Research, vol. 26, p. 654, 2013.

[22] Y. H. Li and F. W. Zhang, "Clinical observation of astragalus injection combined with dopamine in the treatment of cor pulmonale complicated with congestive heart failure," Cardiovascular Disease Journal of Integrated Traditional Chinese and Western Medicine, vol. 6, p. 155, 2018.

[23] X. Qu, "Clinical observation on 80 cases of congestive heart failure treated with astragalus injection combined with western medicine," Chinese Community Doctors, p. 30, 2014.

[24] J. Z. Su and H. Tan, "Effect of astragalus injection on the quality of life and N-terminal pro brain natriuretic peptide in patients with chronic heart failure," Jilin Journal of Chinese Medicine, vol. 37, p. 678, 2017.

[25] X. S. Wang, "Observation on the efficacy of betaloc combined with astragalus in the treatment of chronic heart failure," China Clinical Practical Medicine, vol. 2, p. 85, 2008.

[26] M. F. Wei, "Isosorbide dinitrate combined with astragalus injection in the treatment of 23 cases of cor pulmonale with heart failure," Anthology of Medicine, vol. 21, p. 490, 2002.

[27] J. Yan, "Clinical observation on 48 cases of chronic congestive heart failure treated by astragalus injection combined with western medicine," Chinese Community Doctors, vol. 29, p. 22, 2013.

[28] W. Yin, "Clinical observation of amrinone combined with astragalus injection in the treatment of heart failure in patients with chronic cor pulmonale," Chinese Journal of Modern Medicine, vol. 3, p. 35, 2003.

[29] Y. Q. Yuan and W. H. Yang, "Treatment of 500 patients of cholasma with Chinese herbal medicine combined with paraamnomethyl benzoic acid," China's Naturopathy, vol. 10, p. 4, 2002.

[30] L. H. Zhai, M. Wang, J. M. Yue, and Y. Z. Ma, "Clinical observation of astragalus injection in the treatment of congestive heart failure," Shanghai Medical & Pharmaceutical Journal, p. 10, 1995.

[31] S. Zhang, P. Shi, and L. Ma, "Short-term effect of astragalus injection on end-stage heart failure in patients with ischemic cardiomyopathy," Liaoning Journal of Traditional Chinese Medicine, vol. 42, p. 297, 2015.

[32] Y. Zhang, "Clinical observation on 86 cases of chronic congestive heart failure treated with astragalus injection," Chinese Community Doctors, vol. 28, p. 14, 2012.

[33] F. R. Zhao and D. B. Zhang, "Effect of astragalus injection on 51 cases of chronic heart failure and its effect on serum galactose lectin-3 and b-type brain natriuretic peptide," China Pharmaceuticals, vol. 24, p. 22, 2015.

[34] Y. Zhao, S. H. Yan, H. D. Wang, and X. Y. Wang, "The therapeutic effect of astragalus injection on chronic heart failure and its effect on MDA, HO-1 and NO," Chinese Archives of Traditional Chinese Medicine, vol. 35, p. 2055, 2017.

[35] Z. H. Zhong, X. B. Luo, and L. Li, "Observation of clinical effects of astragalus injection in treatment of 59 patients with chronic congestive heart failure," Medical Journal of Chinese People's Health, vol. 28, p. 60, 2016.

[36] Z. L. Zhou, P. Yu, D. Lin, L. Z. Liang, and P. Lin, "Study on effect of astragalus injection in treating congestive heart failure," Chinese Journal of Integrated Traditional and Western Medicine, vol. 21, p. 747, 2001.

[37] B. Wang and K. L. Chen, "Observation on 51 cases of cor pulmonale complicated with heart failure and respiratory failure treated with routine therapy and astragalus injection," Journal of Practical Traditional Chinese Medicine, vol. 15, 1999.

[38] S. A. Hunt, W. T. Abraham, M. H. Chin et al., "ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American college of cardiology/American heart association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American college of chest physicians and the international society for heart and lung transplantation: endorsed by the heart rhythm society," Circulation, vol. 112, no. 12, pp. e154-e235, 2005.

[39] K. K. Ho, K. M. Anderson, W. B. Kannel, W. Grossman, and D. Levy, "Survival after the onset of congestive heart failure in Framingham heart study subjects," Circulation, vol. 88, no. 1, pp. 107-115, 1993.

[40] Cardiology Association, "Guidelines for the diagnosis and management of chronic heart failure," Chinese Journal of Cardiology, vol. 35, p. 1076, 2007.

[41] V. M. Ranieri, G. D. Rubenfeld, B. T. Thompson et al., "Acute respiratory distress syndrome the berlin definition," JAMA, vol. 307, no. 23, pp. 2526-2533, 2012.

[42] W. J. Lin, S. S. Li, J. T. Han, Y. B. Tan, L. J. Wang, and S. X. Xian, "The hemodynamic effects of Huangqi injection in the treatment of chronic heart failure: a meta-analysis of clinical controlled trials," Research and Practice on Chinese Medicines, vol. 33, p. 63, 2019.

[43] L. Lv, F.-Y. Wang, X.-X. Ma et al., "Efficacy and safety of Xiangsha Liujunzi granules for functional dyspepsia: a multicenter randomized double-blind placebo-controlled clinical study," World Journal of Gastroenterology, vol. 23, no. 30, pp. 5589-5601, 2017.

[44] Y. Yang, J. Q. Hu, J. Peng, and Y. H. Chen, "Overview of pectoral Qi theory and modern research progress," Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology, vol. 16, p. 2435, 2014.

[45] H. Wei, H. Wu, W. Yu, X. Yan, and X. Zhang, "Shenfu decoction as adjuvant therapy for improving quality of life and hepatic dysfunction in patients with symptomatic chronic heart failure," Journal of Ethnopharmacology, vol. 169, pp. 347-355, 2015.

[46] Y. Hou, S. Wang, Z. Zhao et al., "Clinical assessment of complementary treatment with Qishen Yiqi dripping pills on ischemic heart failure: study protocol for a randomized, double-blind, multicenter, placebo-controlled trial (CACTIHF)," Trials, vol. 14, no. 1, p. 138, 2013.

[47] X. Li, J. Zhang, J. Huang et al., "A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of Qili Qiangxin capsules in patients with chronic heart failure," Journal of the American College of Cardiology, vol. 62, no. 12, pp. 1065-1072, 2013.

[48] J. Tesarz, W. Eich, D. Baumeister, T. Kohlmann, R. D'Agostino, and A. K. Schuster, "Widespread pain is a risk factor for cardiovascular mortality: results from the Framingham heart study," European Heart Journal, vol. 40, no. 20, pp. 1609-1617, 2019.

[49] M. Sellami, O. Slimeni, A. Pokrywka et al., "Herbal medicine for sports: a review," Journal of the International Society of Sports Nutrition, vol. 15, no. 1, p. 14, 2018.

[50] L. Guo, S.-P. Bai, L. Zhao, and X.-H. Wang, "Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival," Medical Oncology, vol. 29, no. 3, pp. 1656-1662, 2012.

[51] Y. X. Ti, Z. X. Pan, and C. Wu, "Intervention of astragalus injection on the kidney injury after cardiopulmonary bypass of infants with congenital heart disease," Zhongguo ZhongXi Yi Jie He Za Zhi, vol. 31, p. 631, 2011.

[52] J. G. Zhang, N. Yang, H. He et al., "Effect of astragalus injection on plasma levels of apoptosis-related factors in aged patients with chronic heart failure," Chinese Journal of Integrative Medicine, vol. 11, no. 3, pp. 187-190, 2005.

[53] Y. Liu and N. Feng, "Nanocarriers for the delivery of active ingredients and fractions extracted from natural products used in traditional Chinese medicine (TCM)," Advances in Colloid and Interface Science, vol. 221, pp. 60-76, 2015.

[54] P. T. Morley, "The promise of traditional Chinese medicine after cardiac arrest: an untapped resource?," Critical Care Medicine, vol. 45, no. 10, pp. 1772-1773, 2017.

[55] P. He, F. J. Li, L. D. Li, and Y. K. Li, "Developing traditional Chinese medicine injection is the need for curing sickness to save patients," Zhongguo Zhong Yao Za Zhi, vol. 42, pp. 1011-1014, 2017.

Yanxiang Ha [ID], (1,2) Po Huang, (1) Yumeng Yan, (1,2) Xiaolong Xu, (1) Bo Li, (1) Yuhong Guo, (1) and Qingquan Liu [ID] (1)

(1) Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing Institute of Traditional Chinese Medicine, Beijing 100010, China

(2) Beijing University of Chinese Medicine, Beijing 100029, China

Correspondence should be addressed to Qingquan Liu; liuqingquan_2003@126.com

Received 22 August 2019; Accepted 27 December 2019; Published 12 February 2020

Academic Editor: Nianping Feng

Caption: Figure 1: In the system of syndrome differentiation and treatment of traditional Chinese medicine, HF, RF, ARDS, and ALI belong to Zong Qi depression.

Caption: Figure 2: Study flow diagram: after searching, a total of 1343 articles were found, 21 of which met the criteria, and were included.

Caption: Figure 5: Risk of bias graph reviews judgements about each risk of bias item presented as percentages across all included 21 studies.

Caption: Figure 8: Astragalus injection vs. routine medicine treatments: outcome: mortality rate.
Figure 3: Based on fixed-effect model, the use of Astragalus injection
can reduce the one-month mortality and one-year mortality of patients
with Zong Qi depression.

Study or subgroup         Experimental       Control      Weight
                                                           (%)
                        Events   Total   Events   Total

1.1.1. 1 month mortality rate

  Fan 2003                1       46       3       46      11.6
  Jia and Xu 2013         0       49       1       49      5.9
  Wang and Chen 1999      0       51       4       38      20.2
  Wei 2002                0       23       2       23      9.7
  Yin 2003                1       46       6       41      24.6
  Yuan and Yang 2002      1       50       3       44      12.4
  Zhao and Zhang 2015     1       50       1       45      4.1
  Zhou et al. 2001        2       42       3       41      11.5
Subtotal (95% CI)                 357              327    100.0
Total events              6                23

Heterogeneity: [chi.sup.2] = 2.82, df = 7 (P = 0.90); [I.sup.2] = 0%
Test for overall effect: Z = 3.15 (P = 0.002)

1.1.2. 1 year mortality rate

  Chang and Wang 2006     3       25       9       25      22.6
  Guo 2005                3       35       5       30      14.0
  Wang 2008               3       24       8       24      20.0
  Wang et al. 2015        4       50       5       50      13.1
  Zhai et al. 1995        0       34       2       17      9.3
  Zhou et al. 2001        4       38       8       36      21.0
Subtotal (95% CI)                 206              182    100.0
Total events              17               37

Heterogeneity: [chi.sup.2] = 2.49, df = 5 (P = 0.78); [I.sup.2] = 0%
Test for overall effect: Z = 3.15 (P = 0.002)

Study or subgroup           Odds ratio

                        M-H, fixed, 95% CI

1.1.1. 1 month mortality rate

  Fan 2003              0.32 [0.03, 3.18]
  Jia and Xu 2013       0.33 [0.01, 8.22]
  Wang and Chen 1999    0.07 [0.00, 1.43]
  Wei 2002              0.18 [0.01, 4.03]
  Yin 2003              0.13 [0.01, 1.13]
  Yuan and Yang 2002    0.28 [0.03, 2.78]
  Zhao and Zhang 2015   0.90 [0.05, 14.79]
  Zhou et al. 2001      0.63 [0.10, 4.00]
Subtotal (95% CI)       0.26 [0.12, 0.61]
Total events

Heterogeneity: [chi.sup.2] = 2.82, df = 7 (P = 0.90); [I.sup.2] = 0%
Test for overall effect: Z = 3.15 (P = 0.002)

1.1.2. 1 year mortality rate

  Chang and Wang 2006   0.24 [0.06, 1.04]
  Guo 2005              0.47 [0.10, 2.15]
  Wang 2008             0.29 [0.07, 1.25]
  Wang et al. 2015      0.78 [0.20, 3.10]
  Zhai et al. 1995      0.09 [0.00, 1.98]
  Zhou et al. 2001      0.41 [0.11, 1.51]
Subtotal (95% CI)       0.38 [0.20, 0.69]
Total events

Heterogeneity: [chi.sup.2] = 2.49, df = 5 (P = 0.78); [I.sup.2] = 0%
Test for overall effect: Z = 3.15 (P = 0.002)

Test for subgroup differences: [chi.sup.2] = 0.44, df = 1 (P = 0.51),
[I.sup.2] = 0%

Figure 4: After 7 days, 14 days, and 28 days of Astragalus injection,
the distance of 6-minute walking test increased.

Study or subgroup               Experimental              Control

                         Mean     SD     Total    Mean     SD     Total

1.2.1. 6MWT for 7d
  Li and Zhang 2018     485.63   26.75    50     352.15   23.86    50
  Zhao et al. 2017       590      59      30      543      66      30
Subtotal (95% CI)                         80                       80

Heterogeneity: [tau.sup.2] = 3595.93; [chi.sup.2] = 26.06, df = 1 (P <
0.00001); [I.sup.2] = 96%
Test for overall effect: Z = 2.12 (P = 0.03)

1.2.2. 6MWT for 14d

  Chang and Wang 2006    330      18      25      315      17      25
  Qu 2014               217.66   41.58    80     181.34   32.21    80
  Su and Tan 2017       352.6     67      30      313     65.3     30
  Yan 2017              211.08   48.2     48     196.65   36.5     48
  Zhang 2012            210.5    45.1     86     198.45   34.5     86
  Zhang et al. 2015      419      71      53      382      53      49
  Zhao and Zhang 2015    346     42.4     50     324.7    38.8     45
Subtotal (95% CI)                         372                      363

Heterogeneity: [tau.sup.2] = 73.21; [chi.sup.2] = 13.81, df = 6
(P = 0.03); [I.sup.2] = 57%
Test for overall effect: Z = 5.03 (P < 0.00001)

1.2.3. 28d 6MWT

  Jia and Xu 2013       326.05   32.14    49     178.25   30.17    49
  Zhong et al. 2016     389.57    65      59     321.66   48.96    59
Subtotal (95% CI)                         108                      108

Heterogeneity: [tau.sup.2] = 3115.26; [chi.sup.2] = 42.02, df = 1
(P < 0.00001); [I.sup.2] = 98%
Test for overall effect: Z = 2.71 (P = 0.007)

Study or subgroup       Weight       Mean difference
                         (%)       IV, random, 95% CI

1.2.1. 6MWT for 7d
  Li and Zhang 2018      51.6    133.48 [123.54, 143.42]
  Zhao et al. 2017       48.4     47.00 [15.32, 78.68]
Subtotal (95% CI)       100.0     91.60 [6.89, 176.31]

Heterogeneity: [tau.sup.2] = 3595.93; [chi.sup.2] = 26.06, df = 1 (P <
0.00001); [I.sup.2] = 96%
Test for overall effect: Z = 2.12 (P = 0.03)

1.2.2. 6MWT for 14d

  Chang and Wang 2006    20.7      15.00 [5.29, 24.71]
  Qu 2014                18.8     36.32 [24.79, 47.85]
  Su and Tan 2017        5.5       39.60 [6.12, 73.08]
  Yan 2017               13.5     14.43 [-2.67, 31.53]
  Zhang 2012             18.3      12.05 [0.05, 24.05]
  Zhang et al. 2015      9.0      37.00 [12.80, 61.20]
  Zhao and Zhang 2015    14.2      21.30 [4.97, 37.63]
Subtotal (95% CI)       100.0     22.62 [13.80, 31.43]

Heterogeneity: [tau.sup.2] = 73.21; [chi.sup.2] = 13.81, df = 6
(P = 0.03); [I.sup.2] = 57%
Test for overall effect: Z = 5.03 (P < 0.00001)

1.2.3. 28d 6MWT

  Jia and Xu 2013        50.6    147.80 [135.46, 160.14]
  Zhong et al. 2016      49.4     67.91 [47.15, 88.67]
Subtotal (95% CI)       100.0    108.31 [30.02, 186.59]

Heterogeneity: [tau.sup.2] = 3115.26; [chi.sup.2] = 42.02, df = 1
(P < 0.00001); [I.sup.2] = 98%
Test for overall effect: Z = 2.71 (P = 0.007)

Test for subgroup differences: [chi.sup.2] = 6.99, df = 2 (P = 0.03),
[I.sup.2] = 71.4%

Figure 6: Risk of bias summary reviews authors' judgements about
each risk of bias item for each included studies.

                        Random     Allocation     Blinding of
                       sequence    concealment    participants
                      generation   (selection    and personnel
                      (selection      bias)      (performance
                        bias)                        bias)

Chang and Wang 2006      (a)           (a)            (a)
Fan 2003                 (c)           (a)            (a)
Guo 2005                 (c)           (a)            (a)
Jia and Xu 2013          (b)           (c)            (b)
Li and Zhang 2018        (b)           (a)            (c)
Qu 2014                  (c)           (c)            (a)
Su and Tan 2017          (b)           (c)            (c)
Wang and Chen 1999       (a)           (a)            (a)
Wang 2008                (c)           (c)            (c)
Wang et al. 2015         (a)           (a)            (a)
Wei 2002                 (c)           (b)            (c)
Yan 2013                 (a)           (a)            (a)
Yin 2003                 (a)           (a)            (a)
Yuan and Yang 2002       (c)           (a)            (a)
Zhai et al. 1995         (c)           (a)            (b)
Zhang 2012               (c)           (a)            (a)
Zhang et al. 2015        (c)           (a)            (a)
Zhao and Zhang 2015      (c)           (a)            (a)
Zhao et al. 2017         (b)           (a)            (a)
Zhong et al. 2016        (c)           (a)            (a)
Zhou et al. 2001         (b)           (a)            (a)

                      Blinding of    Incomplete    Selective
                        outcome     outcome data   reporting
                      assessment     (attrition    (reporting
                      (detection       bias)         bias)
                         bias)

Chang and Wang 2006       (b)           (b)           (a)
Fan 2003                  (a)           (a)           (c)
Guo 2005                  (b)           (a)           (b)
Jia and Xu 2013           (b)           (b)           (c)
Li and Zhang 2018         (c)           (c)           (c)
Qu 2014                   (a)           (a)           (c)
Su and Tan 2017           (a)           (b)           (c)
Wang and Chen 1999        (a)           (b)           (c)
Wang 2008                 (a)           (a)           (a)
Wang et al. 2015          (a)           (c)           (a)
Wei 2002                  (a)           (a)           (a)
Yan 2013                  (a)           (b)           (b)
Yin 2003                  (a)           (c)           (c)
Yuan and Yang 2002        (a)           (b)           (b)
Zhai et al. 1995          (b)           (a)           (a)
Zhang 2012                (a)           (a)           (c)
Zhang et al. 2015         (a)           (b)           (a)
Zhao and Zhang 2015       (a)           (b)           (b)
Zhao et al. 2017          (a)           (a)           (a)
Zhong et al. 2016         (a)           (c)           (c)
Zhou et al. 2001          (a)           (a)           (b)

                      Other bias

Chang and Wang 2006      (c)
Fan 2003                 (c)
Guo 2005                 (c)
Jia and Xu 2013          (c)
Li and Zhang 2018        (c)
Qu 2014                  (c)
Su and Tan 2017          (c)
Wang and Chen 1999       (c)
Wang 2008                (c)
Wang et al. 2015         (b)
Wei 2002                 (c)
Yan 2013                 (c)
Yin 2003                 (b)
Yuan and Yang 2002       (c)
Zhai et al. 1995         (c)
Zhang 2012               (c)
Zhang et al. 2015        (a)
Zhao and Zhang 2015      (c)
Zhao et al. 2017         (c)
Zhong et al. 2016        (c)
Zhou et al. 2001         (c)

Legend:

(a) = red circle with negative sign
(b) = green circle with positive sign
(c) = yellow circle with question mark

Figure 7: GRADE summary of findings table.

Astragalus injection compared to routine medicine treatment for
gathering qi sinking

Patient or population: patients with gathering qi sinking
Setting:

Intervention: astragalus injection
Comparison: routine medicine treatments

Outcomes                     Illustrative comparative risks * (95% CI)

                               Assumed risk       Corresponding risk

                             Routine medicine    Astragalus injection
                                treatments

Case fatality rate-1 month              Study population
Case fatality rate             70 per 1000           19 per 1000
Follow-up: 1 month                                    (9 to 44)

                                    Medium risk population
                               71 per 1000           19 per 1000
                                                      (9 to 45)

Case fatality rate-1 year              Study population
mortality rate                 203 per 1000          88 per 1000
Follow-up: 1 year                                    (48 to 149)

                                     Medium risk population
                               194 per 1000          84 per 1000
                                                     (46 to 142)

6MWT-6MWT 7d                                    The mean 6MWT-6MWT 7d
Follow-up: 7 days                                in the intervention
                                                groups was 91.6 higher
                                                   (6.89 to 176.31
                                                       higher)

6MWT-6MWT 14d                                   The mean 6MWT-6MWT 14d
Follow-up: 14 days                               in the intervention
                                                   groups was 22.62
                                                higher (13.8 to 31.43
                                                       higher)

6MWT-28d 6MWT                                   The mean 6MWT-28d 6MWT
Follow-up: 28 days                               in the intervention
                                                  groups was 108.31
                                                higher (30.02 to 186.6
                                                       higher)

Outcomes                        Relative         No of
                                 effect       participants
                                (95% CI)       (studies)

Case fatality rate-1 month      OR 0.26            68
Case fatality rate           (0.12 to 0.61)   (8 studies)
Follow-up: 1 month

Case fatality rate-1 year       OR 0.38           388
mortality rate               (0.2 to 0.69)    (6 studies)
Follow-up: 1 year

6MWT-6MWT 7d                                      160
Follow-up: 7 days                             (2 studies)

6MWT-6MWT 14d                                     735
Follow-up: 14 days                            (7 studies)

6MWT-28d 6MWT                                     216
Follow-up: 28 days                            (2 studies)

Outcomes                     Quality of the   Comments
                                evidence
                                (GRADE)

Case fatality rate-1 month    (+)(-)(-)(-)
Case fatality rate            Very low (1)
Follow-up: 1 month

Case fatality rate-1 year     (+)(-)(-)(-)
mortality rate                Very low (1)
Follow-up: 1 year

6MWT-6MWT 7d                  (+)(-)(-)(-)
Follow-up: 7 days             Very low (1)

6MWT-6MWT 14d                 (+)(-)(-)(-)
Follow-up: 14 days            Very low (1)

6MWT-28d 6MWT                 (+)(-)(-)(-)
Follow-up: 28 days            Very low (1)

* The basis for the assumed risk (e.g., the median control group risk
across studies) is provided in footnotes. The corresponding risk (and
its 95% confidence interval) is based on the assumed risk is the
comparison group and the relative effect of the intervention (and its
95% CI).

CI: confidence interval; OR: odds ratio;

GRADE working group grades of evidence

High quality: further research is very unlikely to change our
confidence in the estimate of effect.

Moderate quality: further research is likely to have an important
impact on our confidence in the estimate of effect and may change the
estimate.

Low quality: further research is very likely to have an important
impact on our confidence in the estimate of effect and is likely to
change the estimate.

Very low quality: we are very uncertain about the estimate.

(1) No explanation was provided.
COPYRIGHT 2020 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2020 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Ha, Yanxiang; Huang, Po; Yan, Yumeng; Xu, Xiaolong; Li, Bo; Guo, Yuhong; Liu, Qingquan
Publication:Evidence - Based Complementary and Alternative Medicine
Article Type:Disease/Disorder overview
Geographic Code:9CHIN
Date:Mar 1, 2020
Words:7655
Previous Article:Toxicity and Its Mechanism Study of Arecae semen Aqueous Extract in Wistar Rats by UPLC-HDMS-Based Serum Metabolomics.
Next Article:Effects of Herbal Mouthwashes on Plaque and Inflammation Control for Patients with Gingivitis: A Systematic Review and Meta-Analysis of Randomised...
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |